MENU
+Compare
NERV
Stock ticker: NASDAQ
AS OF
Apr 25 closing price
Price
$1.76
Change
+$0.01 (+0.57%)
Capitalization
12.31M

NERV Minerva Neurosciences Forecast, Technical & Fundamental Analysis

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company... Show more

Industry: #Biotechnology
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for NERV with price predictions
Apr 25, 2025

NERV's RSI Indicator climbs out of oversold territory

The RSI Indicator for NERV moved out of oversold territory on April 11, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 35 similar instances when the indicator left oversold territory. In of the 35 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on April 17, 2025. You may want to consider a long position or call options on NERV as a result. In of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for NERV just turned positive on April 16, 2025. Looking at past instances where NERV's MACD turned positive, the stock continued to rise in of 38 cases over the following month. The odds of a continued upward trend are .

NERV moved above its 50-day moving average on April 22, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NERV advanced for three days, in of 225 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NERV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

NERV broke above its upper Bollinger Band on April 23, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for NERV entered a downward trend on April 10, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (14.255). P/E Ratio (9.263) is within average values for comparable stocks, (63.920). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.829). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (254.270).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. NERV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NERV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

NERV is expected to report earnings to rise 91.07% to -107 cents per share on May 13

Minerva Neurosciences NERV Stock Earnings Reports
Q1'25
Est.
$-1.07
Q4'24
Missed
by $1.53
Q3'24
Beat
by $3.98
Q2'24
Missed
by $0.12
Q1'24
Missed
by $0.12
The last earnings report on February 25 showed earnings per share of -56 cents, missing the estimate of 97 cents. With 5.57K shares outstanding, the current market capitalization sits at 12.31M.
A.I. Advisor
published General Information

General Information

a clinical-stage biopharmaceutical company

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
1500 District Avenue
Phone
+1 617 600-7373
Employees
9
Web
https://www.minervaneurosciences.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WEAV10.430.44
+4.40%
Weave Communications
AEI0.950.04
+4.12%
Alset
AKRO41.000.01
+0.02%
Akero Therapeutics
LH228.31-0.27
-0.12%
Laboratory Corp
HQI10.40-0.09
-0.86%
HireQuest

NERV and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NERV has been loosely correlated with CVAC. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if NERV jumps, then CVAC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NERV
1D Price
Change %
NERV100%
+0.57%
CVAC - NERV
38%
Loosely correlated
-0.92%
GPCR - NERV
37%
Loosely correlated
+0.38%
DNLI - NERV
36%
Loosely correlated
+1.23%
AKRO - NERV
33%
Loosely correlated
+0.02%
ETNB - NERV
33%
Poorly correlated
+0.58%
More